BioCentury | Dec 5, 2018
Distillery Therapeutics

Hepatic

...inhibitor BMS-986115 in Phase I testing for solid tumors. Bristol-Myers and Ayala also have AL101 (BMS-906024...
BioCentury | Jun 15, 2018
Clinical News

Ayala reports Phase Ib data for AL101 in solid tumors

...Ayala Pharmaceuticals Inc. (Rehovot, Israel) said once-weekly 4 mg IV AL101 (formerly BMS-906024) led to a...
...Ayala Pharmaceuticals Inc., Rehovot, Israel Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: AL101 (formerly BMS-906024...
...overall response rate (ORR) and pharmacokinetics Status: Phase Ib data Milestone: Start Phase II (2H18) Alicia Parker BMS-906024 American...
BioCentury | Jan 18, 2018
Translation in Brief

A notch for tankyrase

...of human tankyrase knockout cells reveals targets of tankyrase-mediated degradation.” Nature Communications (2017) Mark Zipkin, Staff Writer BMS-906024 BMS-986115 LY3039478 Lynparza nirogacestat RO4929097 AXIN1 Beta-catenin...
BioCentury | Dec 8, 2017
Company News

Newco Ayala in-licenses BMS gamma secretase inhibitors

...Bristol-Myers Squibb Co. (NYSE:BMY) granted newco Ayala Pharmaceuticals Inc. (Rehovot, Israel) exclusive, worldwide rights to BMS-906024...
...Development Dana Gelbaum told BioCentury that the newco plans to start Phase II testing of BMS-906024...
...indication. Gelbaum declined to disclose next steps for BMS-986115, which has completed Phase Ib testing. BMS-906024...
BioCentury | Dec 6, 2017
Company News

Newco Ayala in-licenses BMS gamma secretase inhibitors

...Bristol-Myers Squibb Co. (NYSE:BMY) granted newco Ayala Pharmaceuticals Inc. (Rehovot, Israel) exclusive, worldwide rights to BMS-906024...
...Development Dana Gelbaum told BioCentury that the newco plans to start Phase II testing of BMS-906024...
...indication. Gelbaum declined to disclose next steps for BMS-986115, which has completed Phase Ib testing. BMS-906024...
BioCentury | Nov 17, 2014
Clinical News

BMS-906024: Interim Phase I data

...an open-label, dose-escalation Phase I trial showed that once-weekly 0.6, 4 and 6 mg IV BMS-906024...
...ALT) and aspartate aminotransferase (AST) levels without bilirubin elevation was reported at the 4 mg BMS-906024...
...Hematology meeting in San Francisco in December. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: BMS-906024...
Items per page:
1 - 6 of 6